TABLE A7.
Efficacy by TP53 Statusa in Patients With Baseline ctDNA
| Mutation Status | Lorlatinib (n = 97) | Crizotinib (n = 100) | ||||||
|---|---|---|---|---|---|---|---|---|
| No. (%) | ORR, % (95% CI) | DOR, Months, Median (95% CI) | PFS, Months, Median, (95% CI) | No. (%) | ORR, % (95% CI) | DOR, Months, Median (95% CI) | PFS, Months, Median, (95% CI) | |
| Positive | 41 (42) | 68 (52 to 82) | NR (50.0 to NR) | 51.6 (16.4 to NR) | 42 (42) | 60 (43 to 74) | 5.6 (5.3 to 8.5) | 5.7 (5.4 to 7.2) |
| Negative | 56 (58) | 88 (76 to 95) | NR (62.5 to NR) | NR (60.0 to NR) | 58 (58) | 66 (52 to 78) | 9.2 (7.4 to 11.1) | 9.1 (7.6 to 11.1) |
Abbreviations: ctDNA, circulating tumor DNA; DOR, duration of response; NR, not reached; ORR, objective response rate; PFS, progression-free survival.
a
For TP53 mutation status determination, both known pathogenic or likely pathogenic variants and variants of unknown significance per the ClinVar database were taken into account.